

Source details

Human Genomics

Open Access ⓘ

Scopus coverage years: from 2003 to 2006, from 2008 to Present

Publisher: Springer Nature

ISSN: 1473-9542 E-ISSN: 1479-7364

Subject area: Pharmacology, Toxicology and Pharmaceutics: Drug Discovery Biochemistry, Genetics and Molecular Biology: Genetics
Biochemistry, Genetics and Molecular Biology: Molecular Medicine
Biochemistry, Genetics and Molecular Biology: Molecular Biology

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore 2020
5.3 ⓘ

SJR 2020
1.414 ⓘ

SNIP 2020
1.018 ⓘ

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

Improved CiteScore methodology

CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020 ▼

$$5.3 = \frac{1.018 \text{ Citations 2017 - 2020}}{191 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ⓘ

$$6.0 = \frac{1.122 \text{ Citations to date}}{188 \text{ Documents to date}}$$

Last updated on 04 July, 2021 • Updated monthly

CiteScore rank 2020 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics — Drug Discovery	#49/145	66th
Biochemistry, Genetics and Molecular Biology — Genetics	#115/325	64th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#) [🔗](#)

Human Genomics

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United Kingdom <small>Universities and research institutions in United Kingdom</small>	Biochemistry, Genetics and Molecular Biology Genetics Molecular Biology Molecular Medicine Pharmacology, Toxicology and Pharmaceutics Drug Discovery	BioMed Central Ltd.	55

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	14739542, 14797364	2003-2006, 2008-2020	Homepage How to publish in this journal

SCOPE

Human Genomics is a peer-reviewed, open access, online journal that focuses on the application of genomic analysis in all aspects of human health and disease, as well as genomic analysis of drug efficacy and safety, and comparative genomics. Topics covered by the journal include, but are not limited to: pharmacogenomics, genome-wide association studies, genome-wide sequencing, exome sequencing, next-generation deep-sequencing, functional genomics, epigenomics, translational genomics, expression profiling, proteomics, bioinformatics, animal models, statistical genetics, genetic epidemiology, human population genetics and comparative genomics.




 [Join the conversation about this journal](#)

 Quartiles



FIND SIMILAR JOURNALS

options 

1 BMC Medical Genomics GBR 79% <small>similarity</small>	2 Frontiers in Genetics CHE 77% <small>similarity</small>	3 Annals of Human Genetics GBR 73% <small>similarity</small>	4 Human Genetics DEU 73% <small>similarity</small>	5 Journal of Human Genetics GBR 71% <small>similarity</small>
--	---	--	--	---



■ Cites / Doc. (4 years)
■ Cites / Doc. (3 years)
■ Cites / Doc. (2 years)



Human Genetics

Q1 Drug Discovery

SJR 2020 1.41

powered by scopus.com

Show this widget in your own website

Just copy the code below and paste within your html code:

https://www.scir

SCImago Graphica

Explore, visually communicate and make sense of data with our new **free tool**.

Get it

Install & Configure Chrome

Secure your network and endpoints with built-in malware & phishing protection

Google [Learn More](#)

Metrics based on Scopus® data as of April 2021

SCOPUS Indexed Journals

Mathematics Journals

Publish paper in peer review SCOPUS and Mathematical Reviews indexed journals

publication.com

OPEN

Leave a comment

Name

Email
(will not be published)



Search

Explore journals

Get published

About BMC

Login

Menu



Human Genomics

[Home](#) [About](#) [Articles](#) [Submission Guidelines](#)

About

[Contact](#)

[Editorial Board](#)

Editorial Board

Editor-in-Chief

Vasilis Vasiliou, *Yale University, USA*

Associate Editors

Bassam R Ali, *United Arab Emirates University, UAE*

Stylianos E Antonarakis, *University of Geneva Medical School, Switzerland*

Elsbeth Bruford, *HUGO Gene Nomenclature Committee, UK*

Piero Carninci, *Human Technopole, Milan, Italy*

David N Cooper, *Cardiff University, United Kingdom*

Matt Field, *James Cook University, Australia*

Takashi Gojobori, *King Abdullah University of Science and Technology, Saudi Arabia*

Nicholas Katsanis, *Rescindo Therapeutics Inc., Cary, NC, USA*

Poh-San Lai, *National University of Singapore, Singapore*

Ly Le, *Ho Chi Minh City International University, Vietnam*

Tesfaye B Mersha, *Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH, USA*

Andrew A Monte, *University of Colorado-Denver, USA*

Giuseppe Novelli, *University of Rome Tor Vergata, Italy*

George Patrinos, *University of Patras, Greece*

Jürgen Reichardt, *James Cook University, Australia*

Xiaoming Shi, *National Institute of Environmental Health, China*

Angela Solano, *University of Buenos Aires, Argentina*

Ning Sun, *Yale School of Medicine, New Haven, CT, USA*

Tychele N. Turner, *Washington University School of Medicine, St. Louis, MO, USA*

Kirill A Veselkov, *Imperial College London, UK*

Ingrid Winship, *University of Melbourne, Australia*

Yong Zhu, *Yale School of Public Health, New Haven, CT, USA*

Section Editors

Gene family updates

Daniel W Nebert, *University of Cincinnati, USA*

Software reviews

Cleo Anastassopoulou, *National and Kapodistrian University of Athens, Greece*
Luisa Azevedo, *University of Porto, Portugal*
Brian P Brooks, *National Eye Institute, USA*
Daniel Buchanan, *University of Melbourne, Australia*
Ruth Chadwick, *Cardiff University, UK*
Jian-Min Chen, *INSERM, France*
Collet Dandara, *University of Cape Town, South Africa*
John Danias, *SUNY Downstate Health Sciences University, USA*
Emmanouil Dermitzakis, *University of Geneva, Switzerland*
Marcus Feldman, *Stanford University, USA*
Lynnette R Ferguson, *University of Auckland, New Zealand*
Qiaomei Fu, *Institute of Vertebrate Paleontology and Paleoanthropology, China*
Diego F Garcia Diaz, *University of Chile, Chile*
J Fielding Hejtmancik, *National Eye Institute, USA*
Momoko Horikoshi, *RUIKEN Center for Integrative Medical Sciences, Japan*
Magnus Ingelman-Sundberg, *Karolinska Institutet, Sweden*
Takeshi Iwata, *Tokyo Medical Center, Japan*
Tamsin Jones, *European Bioinformatics Institute, Hinxton, UK*
Yoichiro Kamatani, *Kyoto University, Japan*
Thomas Karn, *Goethe University Frankfurt, Germany*
Volker Lauschke, *Karolinska Institutet, Sweden*
Charles Lee, *The Jackson Laboratory, USA*
Jane Loveland, *European Bioinformatics Institute, Hinxton, UK*
Stanislas Lyonnet, *INSERM, France*
Collen Masimirembwa, *African Institute of Biomedical Science & Technology, Zimbabwe*
Brian Meyer, *Research Centre King Faisal Specialist Hospital & Research Centre, Saudi Arabia*
Yukihide Momozawa, *RIKEN Center for Integrative Medical Sciences, Japan*
Mikko Niemi, *University of Helsinki, Finland*
Michael Nothnagel, *University of Cologne, Germany*
Atsushi Ogura, *Nagahama Institute of Bioscience and Technology, Japan*
Andrew D Patterson, *Pennsylvania State University, USA*
Gabriela Repetto, *Clínica Alemana-Universidad del Desarrollo, Santiago, Chile*

· Samia Temtamy, *National Research Centre, Egypt*

Jeffrey Townsend, *Yale University, USA*

Louise Warnich, *Stellenbosch University, South Africa*

Carsten Wiuf, *University of Copenhagen, Denmark*

Matt Wright, *Stanford University, USA*

Hongyu Zhao, *Yale University, USA*

0 1 2 3 4

[Submit manuscript](#)

[Editorial Board](#)

[Instructions for Editors](#)

[Sign up for article alerts and news from this journal](#)

Official journal of



[Human Genome Organization](#)

Annual Journal Metrics

Speed

46 days first decision for reviewed manuscripts only
 37 days to first decision for all manuscripts
 113 days from submission to acceptance
 19 days from acceptance to publication

Citation Impact

4.639 - [2-year Impact Factor](#)

 [5-year Impact Factor](#)
 - [Source Normalized Impact per Paper \(SNIP\)](#)

1.414 - [SCImago Journal Rank \(SJR\)](#)

ISSN: 1479-7364

Usage

 [Crossref](#) loads

216 Altmetric Mentions

Submission enquiries: [Access here and click Contact Us](#)

General enquiries: info@biomedcentral.com

[More about our metrics](#)

[Read more on our blogs](#)

[Policies](#)

[Support and Contact](#)

[Receive BMC newsletters](#)

[Accessibility](#)

[Leave feedback](#)

[Manage article alerts](#)

[Press center](#)

[Careers](#)

[Language editing for authors](#)

[Scientific editing for authors](#)

Follow BMC



By using this website, you agree to our [Terms and Conditions](#), [California Privacy Statement](#), [Privacy statement](#) and [Cookies policy](#). [Manage cookies/Do not sell my data](#) we use in the preference centre.

SPRINGER NATURE

© 2021 BioMed Central Ltd unless otherwise stated. Part of [Springer Nature](#).

[Skip to main content](#)

Advertisement

- [Explore journals](#)
- [Get published](#)
- [About BMC](#)
- [Login](#)

Human Genomics

- [Home](#)
 - [About](#)
 - [Articles](#)
 - [Submission Guidelines](#)
-
- [Collections](#)
 - [Supplements](#)

Articles

- [Search by keyword](#)
- [Search by citation](#)



Page 1 of 13

Sort by

1. Implementation and implications for polygenic risk scores in healthcare

Increasing amounts of genetic data have led to the development of polygenic risk scores (PRSs) for a variety of diseases. These scores, built from the summary statistics of genome-wide association studies (GWA...

Authors: John L. Slunecka, Matthijs D. van der Zee, Jeffrey J. Beck, Brandon N. Johnson, Casey T. Finnicum, René Pool, Jouke-Jan Hottenga, Eco J. C. de Geus and Erik A. Ehli

Citation: *Human Genomics* 2021 15:46

Content type: Review

Published on: 20 July 2021

- [View Full Text](#)
- [View PDF](#)

2. **ACER3-related leukoencephalopathy: expanding the clinical and imaging findings spectrum due to novel variants**

Leukodystrophies are the main subgroup of inherited CNS white matter disorders which cause significant mortality and morbidity in early years of life. Diagnosis is mostly based on clinical context and neuroima...

Authors: Ali Zare Dehnavi, Erfan Heidari, Maryam Rasulinezhad, Morteza Heidari, Mahmoud Reza Ashrafi, Mohammad Mahdi Hosseini, Fatemeh Sadeghzadeh, Mohammad-Sadegh Fallah, Noushin Rostampour, Amir Bahraini, Masoud Garshasbi and Ali Reza Tavasoli

Citation: *Human Genomics* 2021 15:45

Content type: Primary research

Published on: 19 July 2021

- [View Full Text](#)
- [View PDF](#)

3. **Coding and noncoding variants in *EBF3* are involved in HADDs and simplex autism**

Previous research in autism and other neurodevelopmental disorders (NDDs) has indicated an important contribution of protein-coding (coding) de novo variants (DNVs) within specific genes. The role of de novo n...

Authors: Evin M. Padhi, Tristan J. Hayeck, Zhang Cheng, Sumantra Chatterjee, Brandon J. Mannion, Marta Byrska-Bishop, Marjolaine Willems, Lucile Pinson, Sylvia Redon, Caroline Benech, Kevin Uguen, Séverine Audebert-Bellanger, Cédric Le Marechal, Claude Férec, Stephanie Efthymiou, Fatima Rahman...

Citation: *Human Genomics* 2021 15:44

Content type: Primary research

Published on: 13 July 2021

- [View Full Text](#)
- [View PDF](#)

4. **High-throughput screening of circRNAs reveals novel mechanisms of tuberous sclerosis complex-related renal angiomyolipoma**

Coronavirus disease 2019 (COVID-19) is a global health problem that causes millions of deaths worldwide. The clinical manifestation of COVID-19 widely varies from asymptomatic infection to severe pneumonia and...

Authors: Laksmi Wulandari, Berliana Hamidah, Cennikon Pakpahan, Nevy Shinta Damayanti, Neneng Dewi Kurniati, Christophorus Oetama Adiatmaja, Monica Rizky Wigianita, Soedarsono, Dominicus Husada, Damayanti Tinduh, Cita Rosita Sigit Prakoeswa, **Anang Endaryanto**, Ni Nyoman Tri Puspaningsih, Yasuko Mori, Maria Inge Lusida, Kazufumi Shimizu...

Citation: *Human Genomics* 2021 15:29

Content type: Primary research

Published on: 17 May 2021

- [View Full Text](#)
- [View PDF](#)

19. Whole genome sequencing reveals a frameshift mutation and a large deletion in YY1AP1 in a girl with a panvascular artery disease

Rare diseases are pathologies that affect less than 1 in 2000 people. They are difficult to diagnose due to their low frequency and their often highly heterogeneous symptoms. Rare diseases have in general a hi...

Authors: Víctor Raggio, Nicolas Dell'Oca, Camila Simoes, Alejandra Tapié, Conrado Medici, Gonzalo Costa, Soledad Rodriguez, Gonzalo Greif, Estefania Garrone, María Laura Rovella, Virginia Gonzalez, Margarita Halty, Gabriel González, Jong-Yeon Shin, Sang-Yoon Shin, Changhoon Kim...

Citation: *Human Genomics* 2021 15:28

Content type: Primary research

Published on: 10 May 2021

- [View Full Text](#)
- [View PDF](#)

20. COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy

COVID-19 has engulfed the world and it will accompany us all for some time to come. Here, we review the current state at the milestone of 1 year into the pandemic, as declared by the WHO (World Health Organiza...

Authors: Giuseppe Novelli, Michela Biancolella, Ruty Mehrian-Shai, Vito Luigi Colona, Anderson F. Brito, Nathan D. Grubaugh, Vasilis Vasiliou, Lucio Luzzatto and Juergen K. V. Reichardt

- [1](#)
- [2](#)
- [3](#)
- [4](#)
- [5](#)
- ...
- [13](#)
- [Next page](#)

[Submit manuscript](#)

- [Editorial Board](#)
- [Instructions for Editors](#)
- [Sign up for article alerts and news from this journal](#)
- **Official journal of**



- [Human Genome Organization](#)

Follow

- [Follow us on Twitter](#)

Annual Journal Metrics

- **Speed**
 - 46 days first decision for reviewed manuscripts only
 - 37 days to first decision for all manuscripts
 - 113 days from submission to acceptance
 - 19 days from acceptance to publication

Citation Impact

- 4.639 - [2-year Impact Factor](#)
- 4.860 - [5-year Impact Factor](#)
- 1.018 - [Source Normalized Impact per Paper \(SNIP\)](#)
- 1.414 - [SCImago Journal Rank \(SJR\)](#)

Usage

387,300 Downloads

216 Altmetric Mentions

- [More about our metrics](#)

Advertisement

Human Genomics

ISSN: 1479-7364

Contact us

- Submission enquiries: [Access here and click Contact Us](#)
- General enquiries: info@biomedcentral.com

- [Read more on our blogs](#)
- [Receive BMC newsletters](#)
- [Manage article alerts](#)
- [Language editing for authors](#)
- [Scientific editing for authors](#)

- [Policies](#)
- [Accessibility](#)
- [Press center](#)

- [Support and Contact](#)
- [Leave feedback](#)
- [Careers](#)

Follow BMC

- [BMC Twitter page](#)
- [BMC Facebook page](#)
- [BMC Weibo page](#)


By using this website, you agree to our [Terms and Conditions](#), [California Privacy Statement](#), [Privacy statement](#) and [Cookies policy](#). [Manage cookies/Do not sell my data](#) we use in the preference centre.

PRIMARY RESEARCH

Open Access

Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients



Laksmi Wulandari^{1†}, Berliana Hamidah^{2†}, Cennikon Pakpahan^{2,3†}, Nevy Shinta Damayanti⁴, Neneng Dewi Kurniati⁵, Christophorus Oetama Adiatmaja^{6,7}, Monica Rizky Wigianita⁶, Soedarsono¹, Dominicus Husada⁸, Damayanti Tinduh⁹, Cita Rosita Sigit Prakoeswa¹⁰, Anang Endaryanto⁸, Ni Nyoman Tri Puspaningsih^{11,12}, Yasuko Mori¹³, Maria Inge Lusida^{14,15}, Kazufumi Shimizu^{13,16} and Delvac Oceandy^{17*} 

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a global health problem that causes millions of deaths worldwide. The clinical manifestation of COVID-19 widely varies from asymptomatic infection to severe pneumonia and systemic inflammatory disease. It is thought that host genetic variability may affect the host's response to the virus infection and thus cause severity of the disease. The SARS-CoV-2 virus requires interaction with its receptor complex in the host cells before infection. The transmembrane protease serine 2 (TMPRSS2) has been identified as one of the key molecules involved in SARS-CoV-2 virus receptor binding and cell invasion. Therefore, in this study, we investigated the correlation between a genetic variant within the human *TMPRSS2* gene and COVID-19 severity and viral load.

Results: We genotyped 95 patients with COVID-19 hospitalised in Dr Soetomo General Hospital and Indrapura Field Hospital (Surabaya, Indonesia) for the TMPRSS2 p.Val160Met polymorphism. Polymorphism was detected using a TaqMan assay. We then analysed the association between the presence of the genetic variant and disease severity and viral load. We did not observe any correlation between the presence of TMPRSS2 genetic variant and the severity of the disease. However, we identified a significant association between the p.Val160Met polymorphism and the SARS-CoV-2 viral load, as estimated by the Ct value of the diagnostic nucleic acid amplification test. Furthermore, we observed a trend of association between the presence of the C allele and the mortality rate in patients with severe COVID-19.

Conclusion: Our data indicate a possible association between TMPRSS2 p.Val160Met polymorphism and SARS-CoV-2 infectivity and the outcome of COVID-19.

Keywords: COVID-19, TMPRSS2, Polymorphism

* Correspondence: delvac.oceandy@manchester.ac.uk

[†]Laksmi Wulandari, Berliana Hamidah and Cennikon Pakpahan contributed equally to this work

¹⁷Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Coronavirus disease 2019 (COVID-19) is the biggest pandemic in the twenty-first century so far. Since the declaration of the pandemic by the World Health Organization (WHO), more than 110 million cases with more than 2.4 million deaths worldwide have been recorded as per mid-February 2021 [1]. COVID-19 is caused by an infection with the SARS-CoV-2 virus, which typically infects cells in the respiratory tract. The clinical presentations of COVID-19 range widely from asymptomatic infection to lethal pneumonia. It is known that three major factors, i.e. age, gender and the presence of underlying diseases, play a major role in determining COVID-19 severity [2–4]. However, it is not clear whether genetic variability contributes significantly to the clinical outcomes of COVID-19 patients.

One important factor that may play a crucial role in determining COVID-19 severity is the interaction between the virus and the host cells. SARS-CoV-2 infects the host cells by binding with its receptor on the surface of the host cell membrane. The main receptor for the SARS-coronavirus family is the angiotensin-converting enzyme 2 (ACE2) [5]. It is known that the spike (S) protein of SARS-CoV-2 mediates the binding of the virus to the ACE2 protein [6]. Considering the importance of virus receptor binding during the infection, it is logical to hypothesise that genetic variations within the gene encoding ACE2 may be associated with the degree of infection and hence the severity of the disease. Surprisingly, studies have reported no correlation between the genetic variations in the human ACE2 gene and the severity of COVID-19 [7], as well as the previous severe acute respiratory syndrome (SARS) [8].

In addition to ACE2, several other molecules are also involved in the process of SARS-CoV-2 virus entry. For example, transmembrane protease serine 2 (TMPRSS2) [9] and neuropilin-1 (NRP1) [10] have been identified as co-receptors for SARS-CoV-2 that play a crucial role during virus entry. These molecules are important in mediating virus entry; for example, TMPRSS2 is known to facilitate the cleavage of the S protein, enabling membrane fusion and endocytic entry of the virus particles [11]. This has prompted us to hypothesise that genetic variability within the TMPRSS2 gene may play a role in determining SARS-CoV-2 infection.

A recent analysis based on computational modelling suggested that out of more than eleven thousand single nucleotide polymorphisms (SNPs) within the human TMPRSS2 gene (dbSNP, NCBI) only 21 SNPs with minor allele frequency (MAF) between 0.01 and 0.95 were predicted to affect the function of the protein [12]. Of these 21 SNPs, only two SNPs are missense variants (rs12329760 and rs75603675). The rs12329760 polymorphism (also known as p.Val160Met variant) has been

shown in several studies to play a role in mediating the risk for prostate cancer, confirming clinical consequences of this genetic variant [13–16]. Therefore, in this study, we focused on studying the association between the p.Val160Met variant of the TMPRSS2 gene and the severity, viral load and clinical outcomes of COVID-19 patients. Although we did not find any correlation between the p.Val160Met polymorphism and disease severity, we observed a possible association between the TMPRSS2 pVal160Met variant and the viral load in COVID-19 patients.

Results

Characteristics of patients

Characteristics of COVID-19 patients included in this study are described in Table 1. Age distributions were significantly different between patients with asymptomatic and mild versus moderate and severe COVID-19. There was a significant difference in the sex distribution with a higher proportion of male patients in the symptomatic groups. Significant differences were observed in the proportions of patients with underlying diseases between the asymptomatic and mild patients versus moderate and severe groups. As expected, the patients in the asymptomatic and mild COVID-19 groups displayed a significantly lower frequency of underlying diseases compared with the moderate and severe groups, including diabetes (P value < 0.001), cardiovascular disease (P value = 0.009) and liver disease (P value = 0.007).

TMPRSS2 p.Val160Met polymorphism and COVID-19 severity

The TMPRSS2 p.Val160Met polymorphism (rs12329760) was successfully detected in all patients. The genotype and allele frequencies of this SNP are shown in Additional file 1. We observed a deviation of the allele frequency from Hardy–Weinberg equilibrium ($\chi^2 = 6.72$, P value = 0.035). However, the frequency of C allele (61.6%) and T allele (38.4%) in this study population seemed to be comparable with the reported frequency in the Asian population (dbSNP, NCBI) (Additional file 1).

The cross-tab analysis for the genotype and severity groups indicated no significant difference in the distribution of TMPRSS2 p.Val160Met polymorphism among the four groups of patients (Table 2). There were higher odds ratios in subjects with CC and CT genotypes to get symptomatic or more severe COVID-19 than those with TT genotype although they did not reach statistical significance (Table 3).

TMPRSS2 p.Val160Met polymorphism and viral load

Next, we analysed the association between polymorphism and the viral load. All of the patients had positive results of the nucleic acid amplification testing (NAAT)

Table 1 Demographic and baseline characteristics

Variables	Asymptomatic (N=21)	Mild (N=12)	Moderate (N=32)	Severe (N=30)	All patients (N=95)	P value chi-square test (unless otherwise stated)
Age (years)	33.9 ± 2.4*	35.6 ± 2.7*	52.3 ± 2.1	48.8 ± 1.5	44.7 ± 1.3	*P<0.001 versus moderate and severe groups (ANOVA)
Gender (%)						
Male	8 (38.1%)	10 (83.3%)	19 (59.4%)	23 (76.7%)	60 (63.2%)	0.016
Female	13 (61.9%)	2 (16.7%)	13 (40.6%)	7 (23.3%)	35 (36.8%)	
Underlying diseases (%)						
Diabetes	0	0	9 (28.1%)	12 (40%)	21 (22.1%)	<0.001
CVD	2 (9.5%)	0	13 (40.6%)	10 (33.3%)	25 (26.3%)	0.009
Liver diseases	0	0	4 (12.5%)	9 (30%)	13 (13.7%)	0.007
Kidney diseases	0	0	4 (12.5%)	1 (3.3%)	5 (5.3%)	0.144
Lung diseases	0	0	3 (9.4%)	0	3 (3.2%)	0.107
Others	0	0	3 (9.4%)	2 (6.7%)	5 (5.3%)	0.386

for the SARS-CoV-2 virus. The Ct value was used as the semi-quantitative predictor of the viral load. Since Ct values vary depending on the qPCR system and the methodology of the NAAT, we only focused our analysis on patients with moderate and severe COVID-19. All of the patients in these groups were hospitalised in Dr Soetomo General Academic Hospital; hence, the NAAT was conducted in the same place, i.e. the Clinical Pathology and Microbiology Laboratory, Dr Soetomo General Academic Hospital. We analysed the Ct values of the first NAAT, which were conducted at the time when the patients were admitted to the hospital. A low Ct value is likely associated with a high viral load, whereas a high Ct value is likely to be associated with a low viral load. As illustrated in Fig. 1a, a significant difference was observed in the Ct value between patients with a TT genotype and patients with a CC genotype ($P = 0.04$), indicating a possible association of this genotype with a higher viral load. The Pearson correlation analysis also indicated a trend of decreasing Ct value with the presence of the C allele ($P = 0.08$). In contrast, we did not

observe any difference and correlation between Ct value and patients' gender (Fig. 1b) as well as between Ct value and age (Fig. 1c). Additionally, there was no difference in Ct value between patients with moderate and severe COVID-19 (Fig. 1d).

TMPRSS2 polymorphism and patients' outcome

During the course of the study, all of the patients with mild COVID-19 recovered, whereas 9.4% of the patients with moderate COVID-19 and 60% of the patients with severe COVID-19 died. When we analysed the association between TMPRSS2 p.Val160Met polymorphism and the patients' outcomes, we did not find any association between the polymorphism and mortality in the moderate COVID-19 group (Table 4). However, we observed a trend of association in the severe group, in which a higher proportion of patients who died of COVID-19 had a CC genotype ($P = 0.042$ using the linear-by-linear association chi-squared test) (Table 4). We also observed an increasing trend of odds

Table 2 Genotype and allele frequencies of the TMPRSS2 p.Val160Met polymorphism according to COVID-19 severity

	Asymptomatic (N=21)		Mild (N=12)		Moderate (N=32)		Severe (N=30)		Chi-square test
	N	%	N	%	N	%	N	%	
Genotype (amino acids)									
CC (Val/Val)	8	38.1	4	33.3	17	53.1	13	43.4	$\chi^2 = 3.11$
CT (Val/Met)	7	33.3	5	41.7	11	34.4	10	33.3	$P=0.79$
TT (Met/Met)	6	28.6	3	25	4	12.5	7	23.3	
Allele									
C Allele	23	54.8	13	54.2	45	70.3	36	60	$\chi^2 = 3.51$
T Allele	19	45.2	11	45.8	19	29.7	24	40	$P=0.32$

Table 3 Analysis of odds ratio for the risk of symptomatic or more severe COVID-19 in each genotype

Genotype	Asymptomatic (N=21) vs all symptomatic cases (N=74)			Asymptomatic and mild (N=33) vs moderate and severe cases (N=62)		
	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value
CC	1.821	0.533–6.219	0.335	2.045	0.676–6.185	0.255
CT	1.592	0.447–5.664	0.471	1.432	0.462–4.437	0.573
TT	1	Reference		1	Reference	

ratios of mortality in subjects with CC and CT genotypes (Table 5).

Discussion

This is the first study to demonstrate a possible association between TMPRSS2 p.Val160Met polymorphism and the degree of SARS-CoV-2 viral load as indicated by the Ct value of NAAT in patients with COVID-19.

Patients with a CC genotype, which corresponds to the presence of valine amino acid, tend to display a lower Ct value (high viral load). We also found a trend of association between a CC genotype and mortality in a group of patients with severe COVID-19.

It is widely known that the SARS-CoV-2 virus enters the host cells via binding with ACE2, which acts as the main receptor for the viral particles [6, 9, 17]. The spike




Table 4 Association between *TMPRSS2* polymorphism with mortality/survival in patients with moderate-severe COVID-19

	Moderate COVID-19 (N=32)		Severe COVID-19 (N=30)	
	Recovered (N=29, 90.6%)	Died (N=3, 9.4%)	Recovered (N=12, 30%)	Died (N=18, 60%)
Genotype (amino acids)				
CC (Val/Val)	16 (50%)	1 (3.1%)	3 (10 %)	10 (33.3%)
CT (Val/Met)	10 (31.3%)	1 (3.1%)	4 (13.3%)	6 (20 %)
TT (Met/Met)	3 (9.4%)	1 (3.1%)	5 (16.7%)	2 (6.7%)
	Chi-square test $P=0.498$		Chi-square test $P=0.109$	
	Linear-by-linear chi-square association test $P=0.299$		Linear-by-linear chi-square association test $P=0.042$	

(S) protein of the SARS-CoV-2 virus consists of two sub-units: the S1 sub-unit, which is important for virus attachment, and the S2 sub-unit, which is essential for membrane fusion. ACE2 molecule can bind to the S1 protein to promote virus invasion into the host cells [6, 18]. In human, ACE2 is expressed in many organs, such as the upper respiratory tract, alveolar epithelial cells, vascular endothelial cells and macrophages [5].

In addition to ACE2, several other molecules are involved in SARS-CoV-2 virus binding and cell penetration. The S protein needs to be cleaved to activate the endocytic route of virus entry and to enable membrane fusion. It has been reported that several host proteases are involved in the process of S protein breakdown. These include *TMPRSS2*, cathepsin L, furin [9] and NRP1 [10].

TMPRSS2 is a serine protease that can prime the S protein of SARS-CoV-2 to enable cell penetration [9, 19]. The expression of *TMPRSS2* in VeroE6 cells facilitates SARS-CoV-2 virus entry and promotes virus invasion [9]. Notably, treatment with the *TMPRSS2* inhibitor (camostat mesylate) significantly reduced SARS-CoV-2 virus infection [9]. Moreover, *TMPRSS2* is also involved in SARS-CoV-1 virus infection [20], supporting the idea of the critical role of this molecule in mediating virus entry.

The human *TMPRSS2* gene is located in chromosome 21.q22.3. It encodes protein that contains a transmembrane domain, low-density lipoprotein receptor class A (LDLRA) domain, scavenger receptor cysteine-rich (SRCR) domain and serine protease catalytic domain [21]. At least six nucleotide variants within the human *TMPRSS2* coding region that cause amino acid substitutions have been identified. These include p.Val160Met,

p.Gly181Arg, p.Arg240Cys, p.Gly259Ser, p.Pro335Leu and p.Gly432Ala [22]. Of these variants, the p.Val160Met variant is often associated with diseases, notably prostate cancer. A study conducted on a Japanese population indicated that the *TMPRSS2* p.Val160Met variant (also known as Met160Val polymorphism) was associated with the risk of sporadic prostate cancer [16]. Also, a study conducted on 214 patients with prostate cancer demonstrated that the T allele of this variant, which is associated with the presence of Met amino acid, was associated with *TMPRSS2*-ERG fusion and, thus, might be important in prostate cancer pathogenesis [23].

Our data indicate that in our study population the proportion of the genotypes deviates from the Hardy-Weinberg equilibrium. This deviation could be due to natural selection, non-random mating, genetic drift, or gene flow [24]. In our study population, the deviation was likely due to the higher number of subjects with CC and TT genotypes than the expected values (Additional file 1). However, the frequency of subjects with heterozygous genotype (CT) was lower than the expected value. Therefore, it is unlikely that the deviation was due to natural selection or advantages of a specific allele because the number of subjects with homozygous genotypes of both the T and C alleles was higher than the expected values, implying that there was no specific advantage of either the T or C allele. Thus, it is more likely that the deviation was due to non-random mating or genetic drift, which is more likely to occur in a small study population.

Recent bioinformatic analysis studying the functional effects of nucleotide variants within the human *TMPRSS2* gene revealed that the p.Val160Met variant was the

Table 5 Analysis of odds ratio for the mortality in moderate and severe COVID-19 patients

Genotype	Odds ratio of mortality in moderate COVID-19			Odds ratio of mortality in severe COVID-19		
	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value
CC	0.188	0.009-3.895	0.241	8.33	1.034-67.14	0.062
CT	0.3	0.014-6.382	0.423	3.75	0.473-29.75	0.335
TT	1	Reference		1	Reference	

most likely variant that might affect TMPRSS2 protein function and stability [12]. Furthermore, a computational analysis to predict the effects of polymorphism on protein structure suggested that the Val160Met substitution might create a pocket protein by influencing several amino acid residues, which might affect TMPRSS2 structure and its role in SARS-CoV-2 cell entry [12]. Possible changes in TMPRSS2 function and/or structure due to the Val160Met substitution might explain our findings on the association of this SNP with the viral load in COVID-19 patients. Alteration of TMPRSS2 function/structure will likely affect the binding of the S protein to ACE2 or the membrane fusion process. Reduction in TMPRSS2 enzymatic activity may decrease the furin cleavage of the S1 protein, which may subsequently decrease S2 fusion to the host's cell membrane. However, further studies at the molecular level are required to prove this hypothesis, for example, by generating recombinant TMPRSS2 proteins bearing the variants and testing them in an *in vitro* model of SARS-CoV-2 cell infection.

Despite the association between pVal160Met polymorphism and the Ct value, we did not find any correlation between the variant and COVID-19 severity. This might be due to other confounding factors that strongly contribute to the severity of COVID-19. It is believed that factors, such as age [3], gender [25] and pre-existing diseases (hypertension, diabetes, CVD and lung disease) [4], strongly correlate with the risk of severe COVID-19. Further analysis with a larger study population is required to control these confounding variables. Interestingly, in patients with severe COVID-19, we observed a trend of association between this polymorphism and the mortality of COVID-19 patients. However, this requires further confirmation in studies with a larger sample size.

Several studies have found associations between genetic variations in the patient's genome and COVID-19 severity. Many of the reported polymorphisms were related to genes involved in the development of inflammatory response, for example, polymorphisms in genes related to type 1 interferon immunity [26], polymorphisms in X-chromosomal TLR7 [27] and polymorphisms within genes involved in the interleukin 1 signalling pathway [28]. Our finding indicates a correlation between polymorphism in the gene encoding the virus receptor complex, i.e. TMPRSS2, and COVID-19 severity. Our data are consistent with previous reports on TMPRSS2 polymorphisms and COVID-19 severity. Initial whole genome analysis of 322 COVID-19 patients in a Chinese population observed a decreasing allele frequency of the TMPRSS2 rs12329760 variant among patients with severe disease compared with patients with mild COVID-19 [28], indicating the importance of TMPRSS2 in COVID-19. Consistently, studies on Italian

COVID-19 patients also demonstrated the role of genetic polymorphisms within the *TMPRSS2* gene in determining COVID-19 severity. An observation on 133 COVID-19 patients found a difference in frequency of this variant in the COVID-19 patient cohort compared with the frequency in the reference databases [29]. In particular, in-depth analysis of available data from the COVID-19 Host Genetic Initiative (HGI) [30] suggested a significant association between *TMPRSS2* gene polymorphism rs12329760 with severe/hospitalised COVID-19 [31]. However, further analysis on the available HGI data (<https://app.covid19hg.org/>) indicated that there was no significant association/difference of polymorphic allele between all SARS-CoV-2-infected subjects and the general population ($P=0.569$). This data is in line with our finding that the polymorphism may have more significant effects in severe cases of COVID-19.

Together, all of the data indicate a crucial involvement of the *TMPRSS2* genetic variation, the p.Val160Met (rs12329760) in particular, in mediating the severity of COVID-19. This will contribute to the growing body of evidence on the crucial involvement of the host's genetic factor in determining susceptibility to and/or severity of COVID-19.

Conclusions

In summary, this is the first study to demonstrate a possible association between *TMPRSS2* p.Val160Met polymorphism and higher viral load in COVID-19 patients. The main limitation of our study is its small sample size. Further large-scale studies are required to validate our findings. Also, by using the Ct value, we can only have an estimate of the viral load. Precise determination of the viral RNA copy number using standard curve qPCR is required to accurately determine the viral load. Mechanistic analysis using a cell culture system is also important to confirm the effects of p.Val160Met on *TMPRSS2* protein function. Nevertheless, our finding may provide new insights into the possibility of using this polymorphism as a biomarker or predictor for COVID-19 severity/clinical outcome. Furthermore, our data may also support the idea of targeting *TMPRSS2* in COVID-19 therapy, as has been done in some clinical trials [32].

Methods

Study design, patients and data collection

This study was a cross-sectional study conducted from June to August 2020. During this period, a total of 95 patients with COVID-19 were enrolled. Patients with moderate and severe COVID-19 ($n = 62$, 65.3%) were hospitalised in Dr Soetomo General Academic Hospital, Surabaya, Indonesia, whilst 33 patients (34.7%) with asymptomatic or mild symptoms were treated in Indra-pura KOGABWILHAN II Hospital, Surabaya, Indonesia.

The diagnosis was confirmed using the nucleic acid amplification test (NAAT) of the oro-nasopharyngeal swab specimens. For patients with moderate and severe symptoms, the NAAT was performed in the Clinical Pathology and Microbiology Laboratory, Dr Soetomo General Academic Hospital, whereas for asymptomatic patients and patients with mild symptoms, the NAAT was conducted in the Centre for Health Laboratory, Surabaya, as part of the standard procedure for COVID-19 management in East Java Province, Indonesia. This study obtained ethical approval from the Local Ethics Committee of Dr Soetomo General Academic Hospital, Surabaya, Indonesia (0006/LOE/301.4.2/V/2020). All patients have signed the informed consent and agreed to participate in this study.

We clustered patients in three categories of disease severity based on criteria according to the WHO Guideline for COVID-19 Management [33] as follows: (i) mild: characterised by the presence of COVID-19 symptoms that meet the case definition of COVID-19 (fever, persistent cough, fatigue, anorexia, shortness of breath, myalgia, sore throat, nose congestion, headache, diarrhoea, nausea and vomiting, anosmia, ageusia) without evidence of viral pneumonia and hypoxia; (ii) moderate: characterized by the presence of the clinical signs of pneumonia but without any signs of hypoxia ($SpO_2 \geq 93\%$); and (iii) severe: characterized by the presence of the clinical signs of pneumonia and one of the clinical signs of respiratory distress (respiratory rate $> 30 \times / \text{min}$, severe respiratory distress, or $SpO_2 < 93\%$).

DNA isolation

Heparinized peripheral blood samples were collected and stored in a -80°C freezer before use. DNA extraction was performed using the QIAamp® Blood DNA Midi kit (cat #51185, Qiagen) according to the manufacturer's recommended protocol. DNA concentrations were determined using a microvolume spectrophotometer (NanoDrop Lite, Thermo Fisher Scientific). The procedures were conducted in the Biosafety Level 3 (BSL 3) Laboratory in the Institute of Tropical Disease, Universitas Airlangga, to reduce the risk of COVID-19 transmission.

Polymorphism detection

The TMPRSS2 polymorphism (rs12329760, TMPRSS2 p.Val160Met also known as TMPRSS2 Met160Val polymorphism) was detected using a TaqMan SNP genotyping assay (Cat #4351379, Applied Biosystems, USA) in accordance with the protocol recommended by the manufacturer. Genotyping was performed using real-time polymerase chain reaction (RT-PCR) with VIC and FAM fluorescent reporters to indicate allelic discrimination. The 7500 Fast Real-Time PCR System (Applied

Biosystems) was used in conjunction with the 7500 software v2.3 (Life Technologies™, Applied Biosystems) to create the allelic discrimination plot.

Data analysis

Statistical analyses were performed using the IBM SPSS Statistics Software ver. 23 (IBM Corp.) or GraphPad Prism ver. 8 (GraphPad Software, LLC). A chi-squared test was used to examine the Hardy–Weinberg equilibriums and to determine the association between categorical variables in the cross-tabulation data. ANOVA with post hoc multiple comparisons was used to analyse numerical data. A *P* value less than 0.05 was considered to be statistically significant.

Abbreviations

COVID-19: Coronavirus disease 2019; SARS: Severe acute respiratory syndrome; SARS-CoV-2: SARS coronavirus 2; TMPRSS2: Transmembrane protease serine 2; ACE2: Angiotensin-converting enzyme 2; NRP1: Neuropilin-1; dbSNP: Database of single nucleotide polymorphism; NAAT: Nucleic acid amplification test; SNP: Single nucleotide polymorphism; LDLRA: Lipoprotein receptor class A; SRCR: Scavenger receptor cysteine-rich; CVD: Cardiovascular disease; HGI: Host genetics initiative

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40246-021-00330-7>.

Additional file 1. Genotype and allele frequencies of the TMPRSS2 p.Val160Met polymorphism in all patients.

Acknowledgements

We thank Aldise M. Nastri, Krisnoadi Rahardjo, Rima R. Prasetya, and Jezzy R. Dewantari (Institute of Tropical Disease, Universitas Airlangga) for the support during laboratory work. We thank Astri N. Amalia and Anisa Octaviani for the administration support.

Authors' contributions

L.W. designed the study, managed the funding, supervised the biological sample collection and collected and analysed the clinical data; B.H. performed the DNA extraction and polymorphism detection and wrote the manuscript; C.P. performed the DNA extraction and polymorphism detection and wrote the manuscript; N.S.D. collected blood samples and clinical data; N.D.K. collected blood samples; M.R.W. collected the clinical data; C.O.A. collected blood samples; S. supervised the blood sample collection, D.H. supervised the blood sample collection; D.T. designed the study and supervised ethical clearance; CRSP. designed the study and supervised the project; A.E. supervised the project; N.N.T.P. supervised the project; Y.M. supervised the project; M.J.L. supervised the project; K.S. supervised the DNA isolation and polymorphism detection; D.O. conceived the original idea, designed the study, performed the data analysis and wrote and edited manuscript. The authors read and approved the final manuscript.

Funding

This work was funded by Mandate Research Grant Special for COVID-19 from Universitas Airlangga (2020).

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

The protocol of the study including biological sample collection and storage of materials and information was approved by the Ethics Committee of Dr Soetomo General Academic Hospital, Surabaya, Indonesia (0006/LOE/301.4.2/V/2020). All patients signed the informed consent form and agreed to participate in this study.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga/Dr Soetomo General Academic Hospital, Surabaya, Indonesia. ²Department of Biomedical Sciences, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. ³Andrology Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. ⁴Indrapura KOGABWILHAN II Hospital, Surabaya, Indonesia. ⁵Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga/Clinical Microbiology Unit, Central Laboratory Installation, Dr Soetomo General Academic Hospital, Surabaya, Indonesia. ⁶Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. ⁷Clinical Pathology Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. ⁸Department of Child Health, Faculty of Medicine, Universitas Airlangga/Dr Soetomo General Academic Hospital, Surabaya, Indonesia. ⁹Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Universitas Airlangga/Dr Soetomo General Academic Hospital, Surabaya, Indonesia. ¹⁰Department of Dermatology Venereology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. ¹¹Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia. ¹²Laboratory of Proteomic, University CoE-Research Center for Bio-Molecule Engineering, Universitas Airlangga, Surabaya, Indonesia. ¹³Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, Japan. ¹⁴Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia. ¹⁵Department of Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. ¹⁶CRC-ERID, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia. ¹⁷Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.

Received: 2 March 2021 Accepted: 4 May 2021

Published online: 17 May 2021

References

- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 2020;20(5):533–4. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1).
- Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ.* 2020;369:m1985.
- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180(7):934–43. <https://doi.org/10.1001/jamainternmed.2020.0994>.
- Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis.* 2020;94:91–5. <https://doi.org/10.1016/j.ijid.2020.03.017>.
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature.* 2003;426(6965):450–4. <https://doi.org/10.1038/nature02145>.
- Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature.* 2020;581(7807):215–20. <https://doi.org/10.1038/s41586-020-2180-5>.
- Novelli A, Biancolella M, Borgiani P, Cocciadiferro D, Colona VL, D'Apice MR, et al. Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. *Hum Genomics.* 2020;14(1):29. <https://doi.org/10.1186/s40246-020-00279-z>.
- Chiu RW, Tang NL, Hui DS, Chung GT, Chim SS, Chan KC, et al. ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. *Clin Chem.* 2004;50(9):1683–6. <https://doi.org/10.1373/clinchem.2004.035436>.
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181(2):271–80 e278. <https://doi.org/10.1016/j.cell.2020.02.052>.
- Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science.* 2020;370(6518):856–60. <https://doi.org/10.1126/science.abd2985>.
- Bestle D, Heindl MR, Limburg H, Van Lam Van T, Pilgram O, Moulton H, Stein DA, Hards K, Eickmann M, Dolnik O et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Sci Alliance.* 2020;3(9):e202000786. <https://doi.org/10.26508/lsa.202000786>.
- Paniri A, Hosseini MM, Akhavan-Nia H. First comprehensive computational analysis of functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among different populations. *J Biomol Struct Dyn.* 2020. <https://doi.org/10.1080/07391102.2020.1767690>.
- Bhanushali A, Rao P, Raman V, Kakate P, Ambekar A, Mandava S, et al. Status of TMPRSS2-ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism. *Prostate Int.* 2018;6(4):145–50. <https://doi.org/10.1016/j.pri.2018.03.004>.
- Giri VN, Ruth K, Hughes L, Uzzo RG, Chen DY, Boorjian SA, et al. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. *BJU Int.* 2011;107(3):466–70. <https://doi.org/10.1111/j.1464-410X.2010.09522.x>.
- Lubieniecka JM, Cheteri MW, Stanford JL, Ostrander EA. Met160Val polymorphism in the TMPRSS2 gene and risk of prostate cancer in a population-based case-control study. *Prostate.* 2004;59(4):357–9. <https://doi.org/10.1002/pros.20005>.
- Maekawa S, Suzuki M, Arai T, Suzuki M, Karo M, Monkawa T, et al. TMPRSS2 Met160Val polymorphism: significant association with sporadic prostate cancer, but not with latent prostate cancer in Japanese men. *Int J Urol.* 2014;21(12):1234–8. <https://doi.org/10.1111/iju.12578>.
- Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. *Cell.* 2020;181(4):894–904 e899. <https://doi.org/10.1016/j.cell.2020.03.045>.
- Cavasotto CN, Lamas MS, Maggini J. Functional and druggability analysis of the SARS-CoV-2 proteome. *Eur J Pharmacol.* 2021;890:173705. <https://doi.org/10.1016/j.ejphar.2020.173705>.
- Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A.* 2020;117(13):7001–3. <https://doi.org/10.1073/pnas.2002589117>.
- Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. *J Virol.* 2011;85(2):873–82. <https://doi.org/10.1128/JVI.02062-10>.
- Thunders M, Delahunt B. Gene of the month: TMPRSS2 (transmembrane serine protease 2). *J Clin Pathol.* 2020;73(12):773–6. <https://doi.org/10.1136/jclinpath-2020-206987>.
- Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. *BMC Med.* 2020;18(1):216. <https://doi.org/10.1186/s12916-020-01673-z>.
- FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. *BMC Cancer.* 2008;8(1):230. <https://doi.org/10.1186/1471-2407-8-230>.
- Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. *Am J Hum Genet.* 2005;76(5):887–93. <https://doi.org/10.1086/429864>.
- Getthard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol Sex Differ.* 2020;11(1):29. <https://doi.org/10.1186/s13293-020-00304-9>.
- Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;370(6515):eabd4570. <https://doi.org/10.1126/science.abd4570>.

27. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of genetic variants among young men with severe COVID-19. *JAMA*. 2020;324(7):663–73.
28. Wang F, Huang S, Gao R, Zhou Y, Lai C, Li Z, et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. *Cell Discov*. 2020;6(1):83. <https://doi.org/10.1038/s41421-020-00231-4>.
29. Latini A, Agolini E, Novelli A, Borgiani P, Giannini R, Gravina P, et al. COVID-19 and genetic variants of protein involved in the SARS-CoV-2 entry into the host cells. *Genes (Basel)*. 2020;11(9):1010. <https://doi.org/10.3390/genes11091010>.
30. COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet*. 2020; 28(6):715–8.
31. Andolfo I, Russo R, Lasorsa VA, Cantalupo S, Rosato BE, Bonfiglio F, et al. Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19. *iScience*. 2021;24(4): 102322.
32. Hofmann-Winkler H, Moerer O, Alt-Epping S, Brauer A, Buttner B, Müller M, et al. Camostat mesylate may reduce severity of coronavirus disease 2019 sepsis: a first observation. *Crit Care Explor*. 2020;2(11):e0284. <https://doi.org/10.1097/CCE.0000000000000284>.
33. World Health Organization: Clinical management of COVID-19: World Health Organization; 2020.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

